{"id":382399,"date":"2026-07-22T13:32:13","date_gmt":"2026-07-22T13:32:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-tx\/382399\/"},"modified":"2026-07-22T13:32:13","modified_gmt":"2026-07-22T13:32:13","slug":"houston-cancer-research-extends-lives-and-elevates-care","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-tx\/382399\/","title":{"rendered":"Houston cancer research extends lives and elevates care"},"content":{"rendered":"<p><img alt=\"Research by Nobel-Prize winner Jim Allison, chairman of the Department of Immunology at\u00a0M.D. Anderson Cancer Center, has led to promising results.\" loading=\"eager\" fetchpriority=\"high\"   style=\"aspect-ratio:3 \/ 2\" class=\"x100 y100 opc bgpc ofcv bgscv block bg-black mnh0px fill\"\/><\/p>\n<p>Research by Nobel-Prize winner Jim Allison, chairman of the Department of Immunology at\u00a0M.D. Anderson Cancer Center, has led to promising results.<\/p>\n<p>MD Anderson Cancer Center<img alt=\"Dr. Daniela Matei, of Houston Methodist\u2019s Neal Cancer Center, specializes in gynecological cancers, including ovarian and endometrial cancers.\" loading=\"lazy\"   style=\"aspect-ratio:3 \/ 2\" class=\"x100 y100 opc bgpc ofct bgsct block bg-black mnh0px fill\"\/><\/p>\n<p>Dr. Daniela Matei, of Houston Methodist\u2019s Neal Cancer Center, specializes in gynecological cancers, including ovarian and endometrial cancers.<\/p>\n<p>Houston Methodist<img alt=\"Dr. Mothaffar Rimawi is executive medical director of the Dan L. Duncan Comprehensive Cancer Center at Baylor St. Luke\u2019s Medical Center.\" loading=\"lazy\"   style=\"aspect-ratio:3 \/ 2\" class=\"x100 y100 opc bgpc ofct bgsct block bg-black mnh0px fill\"\/><\/p>\n<p>Dr. Mothaffar Rimawi is executive medical director of the Dan L. Duncan Comprehensive Cancer Center at Baylor St. Luke\u2019s Medical Center.<\/p>\n<p>Baylor St. Luke\u2019s Medical Center<img alt=\"Dr. Jeffrey Lee, of M.D. Anderson, has focused on abdominal cancers, such as pancreatic, with a secondary specialty in melanoma,\" loading=\"lazy\"   style=\"aspect-ratio:3 \/ 2\" class=\"x100 y100 opc bgpc ofct bgsct block bg-black mnh0px fill\"\/><\/p>\n<p>Dr. Jeffrey Lee, of M.D. Anderson, has focused on abdominal cancers, such as pancreatic, with a secondary specialty in melanoma,<\/p>\n<p>M.D. Anderson\/Photo Courtesy of MD Anderson Ca<img alt=\"\u00a0M.D. Anderson researcher and Nobel-Prize winner Jim Allison's ground-breaking research enabled doctors to enlist the immune system to fight cancer.\u00a0\" loading=\"lazy\"   style=\"aspect-ratio:3 \/ 2\" class=\"x100 y100 opc bgpc ofct bgsct block bg-black mnh0px fill\"\/><\/p>\n<p>\u00a0M.D. Anderson researcher and Nobel-Prize winner Jim Allison&#8217;s ground-breaking research enabled doctors to enlist the immune system to fight cancer.\u00a0<\/p>\n<p>Craig Hartley\/For the Chronicle<\/p>\n<p>The auditorium was packed at the American Society of Clinical Oncology\u2019s annual meeting in June, as doctors and researchers gathered to hear what was likely the most consequential news in decades: New drugs and therapies are changing outcomes for some of the most difficult cancers, including pancreatic, breast and even prostate cancers.<\/p>\n<p>When researchers announced their findings on pancreatic cancer alone, they received a five-minute standing ovation, with usually stoic doctors high-fiving and clapping. Many were moved to tears, said Dr. Mothaffar Rimawi, executive medical director of the Dan L. Duncan Comprehensive Cancer Center at Baylor St. Luke\u2019s Medical Center.<\/p>\n<p>\u201cSome 20,000 people were in tears and on their feet because we finally could target the pathway that causes pancreatic cancer. People were hugging each other because we\u2019re finally making progress. You could see new hope,\u201d said\u00a0Rimawi, a breast oncologist, noting that Baylor St. Luke\u2019s was part of the first phase of the study that lead to the development of daraxonrasib, an oral pill that reduced the risk of death by 60 percent in metastatic pancreatic ductal adenocarcinoma patients.\u00a0<\/p>\n<p class=\"uiTextSmall f aic jcc\">Article continues below this ad<\/p>\n<p>Between\u00a0Baylor St. Luke\u2019s, Houston Methodist, Memorial Hermann and the University of Texas MD Anderson Cancer Center, research on new drugs and ways to treat cancer are not only changing survival rates for some of the most difficult to treat cancers, but it\u2019s also improving the quality of life during and after treatment for many patients.<\/p>\n<p>Dr. Jim Allison, of MD Anderson, earned the 2018 Nobel Price in Physiology or Medicine for discoveries in\u00a0immunotherapy, changing survival rates by finding a way to harness a patient\u2019s immune system to attack cancer cells for a variety of cancers. Allison shared that Nobel Prize with Tasuku Honjo of Japan.<\/p>\n<p>Immunotherapy has been transformative in cancer care, but that isn\u2019t all that\u2019s happening.<\/p>\n<p>Ongoing news from the human genome project &#8212; a longtime project that Baylor participates in &#8212; allows scientists to identify genetic mutations, and the development of artificial intelligence helps physicians analyze mountains of data to provide better and more personalized care.\u00a0<\/p>\n<p class=\"uiTextSmall f aic jcc\">Article continues below this ad<\/p>\n<p>\u201cI don\u2019t think there\u2019s any other field of medicine that\u2019s as exciting as oncology right now. There have been amazing changes in the last 10 years even for cancers that were considered killers,\u201d Dr.\u00a0Daniela Matei of Houston Methodist\u2019s Neal Cancer Center. Matei\u2019s own area of specialty is gynecological cancers, including ovarian and endometrial cancers.\u00a0<\/p>\n<p>Dr. Jeffrey Lee came to MD Anderson after his residency training and has focused on abdominal cancers, such as pancreatic, with a secondary specialty in melanoma, two deadly forms of cancer. With so many years focused on cancers with low survival rates, Lee is excited about the news he can now give patients: There is hope.<\/p>\n<p>\u201cAt MD Anderson, we are tremendously energized by the possibilities. The huge advances in using\u00a0immunotherapy could transform the outcomes of advanced melanoma from a diagnosis that gave patients an average lifespan of just 7 months &#8212; just 3 percent of patients could live five years. Now, more than 60 percent of patients can live for five years,\u201d Lee said.<\/p>\n<p>Lee talked about one pancreatic cancer patient who has lived nine years since his diagnosis. In that time, he has been able to greet seven new grandchildren.<\/p>\n<p>Dr. Julie Rowe, the research director of oncology at the UT Medical School \u00a0and operations director for the Memorial Hermann Cancer Center, specializes in gastrointestinal cancers, including pancreatic, said that Memorial Hermann is involved in two promising Phase 2 clinical trials right now.\u00a0<\/p>\n<p class=\"uiTextSmall f aic jcc\">Article continues below this ad<\/p>\n<p>They are a three-prong attack, combining chemotherapy and\u00a0immunotherapy with radio frequency ablation prompting a whole body response, Rowe said.<\/p>\n<p>Pancreatic cancer isn\u2019t the only one making headlines.<\/p>\n<p>Breast cancer, the most-diagnosed cancer, is now much more survivable. Dr. Jenny Chang, now the CEO of the Houston Methodist Academic Institute, has done groundbreaking work on chemotherapy-resistant tumor-initiating cells in triple-negative breast cancer patients, testing treatments with less toxicity and better results.\u00a0<\/p>\n<p>Hundreds of clinical trials for new drugs and treatment programs for a variety of cancers are underway throughout the Texas Medical Center, and Lee said that MD Anderson has the largest clinical trial program in the world. Last year alone, the cancer center enrolled 10,000 patients in more than 1,500 clinical trials. Also, more than 70 percent of the drugs approved by the FDA have been tested at MD Anderson.<\/p>\n<p>Rimawi, whose specialty is treating breast cancer, is the local principal researcher working on a vaccine that can prevent HER-2 breast cancer from recurring. (Up to 25 percent of early-stage HER-2 patients have a recurrence of the cancer within 10 years.)<\/p>\n<p class=\"uiTextSmall f aic jcc\">Article continues below this ad<\/p>\n<p>Lung cancer, still the number one cancer killer that once came with a six-month prognosis, now finds patients still alive seven or more years after treatment, Rimawi said.<\/p>\n<p>Metastatic melanoma, known as a deadly form of cancer that treatment could barely touch, finds patients living several years after treatment and some can be cured.\u00a0<\/p>\n<p>High-risk prostate cancer patients got good news this year with results from a huge clinical trial that tested the drug\u00a0apalutamide with standard hormone therapy before and after radical prostatectomy. Ultimately, the new treatment reduced the risk of metastasis or death by 20 percent.<\/p>\n<p>Clinicians are using the term \u201cpersonalized care\u201d as the new standard for cancer treatment. What it means is that the new drugs, treatment programs and other therapies can zero in on a patient\u2019s individual genetic makeup and tumors or cancer cells for the best care for each person, instead of broad treatment programs that treat everyone as if they\u2019re the same.<\/p>\n<p>In many cases, less toxic drugs &#8212; for example, less chemotherapy &#8212; can improve the quality of life for patients, lessening or removing side effects that can lead to other health problems. It can also make staying alive more affordable, as there could be fewer drugs or rounds of chemotherapy to pay for, Lee said.<\/p>\n<p class=\"uiTextSmall f aic jcc\">Article continues below this ad<\/p>\n<p>Lee and his staff continues to search for ways to optimize immunotherapy and test new drugs, he said, and one of the more promising areas of work underway is microbiome research, which looks at how our intestinal bacteria helps shape how patients respond to a variety of treatments. He noted it includes transplanting more favorable microbiomes and using probiotics and dietary interventions.\u00a0<\/p>\n<p>Artificial intelligence will only become more important in analyzing data from every stage of research and treatment, Lee said.<\/p>\n<p>\u201cI moved to Houston for medical school and was in awe of the Texas Medical Center, the largest medical center in the world. When I think of the Texas Medical Center, I think that the success of one is the success of all,\u201d\u00a0Rimawi said. \u201cThere is so much collaboration across TMC, getting grants together and leveraging strengths together. So many health systems are trying to do what\u2019s right.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Research by Nobel-Prize winner Jim Allison, chairman of the Department of Immunology at\u00a0M.D. Anderson Cancer Center, has led&hellip;\n","protected":false},"author":2,"featured_media":382400,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[56,58,57],"class_list":["post-382399","post","type-post","status-publish","format-standard","has-post-thumbnail","category-houston","tag-houston","tag-houston-headlines","tag-houston-news"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/382399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/comments?post=382399"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/posts\/382399\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media\/382400"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/media?parent=382399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/categories?post=382399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-tx\/wp-json\/wp\/v2\/tags?post=382399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}